BackMedTech Acquisition - Units (1 Ord Share Class A & 1/3 War) Overview

MedTech Acquisition - Units (1 Ord Share Class A & 1/3 War) Total Liabilities

MedTech Acquisition - Units (1 Ord Share Class A & 1/3 War)'s total liabilities is $58M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$58.17M
7.66% YoYΔ $-4.82M vs prior year quarter

Peer average

Loading

MedTech Acquisition - Units (1 Ord Share Class A & 1/3 War) Total Liabilities History

Loading

MedTech Acquisition - Units (1 Ord Share Class A & 1/3 War) vs. peers: Total Liabilities Comparison

Loading

MedTech Acquisition - Units (1 Ord Share Class A & 1/3 War) Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

MedTech Acquisition - Units (1 Ord Share Class A & 1/3 War) (MTACU) FAQ

The latest total liabilities for MTACU is $58M as of March 2026. That compares with $63M in the prior-year period — down 7.7% year over year. Investors often review this figure alongside MedTech Acquisition - Units (1 Ord Share Class A & 1/3 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, MTACU's total liabilities moved from $63M to $58M — a 7.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in MedTech Acquisition - Units (1 Ord Share Class A & 1/3 War)'s operating scale or balance-sheet position.

A total liabilities figure of $58M for MTACU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MTACU's total liabilities ($58M), review year-over-year change from $63M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.